Menlo Therapeutics' stock dropped 55 percent in premarket trading after announcing its serlopitant failed to meet primary and secondary endpoints in a Phase II clinical trial.
Trovagene announced the activation of its clinical trial site for its Phase 1b/2 multicenter trial of PCM-075 in patients with AML, with Virginia Cancer Specialists and Principal Investigator, Dr. Alexander Spira.